Krishna Institute of Medical Sciences Ltd (KIMS) — Tipsheet

KIMS promoters inject ₹600 cr via warrants to retire debt, fund expansion

Tipsheet Editorial — Sat, 13 Jun 2026 13:02:32 GMT

The preferential issue of 77 lakh warrants at ₹779 each amounts to 15% of revenue. Proceeds will reduce debt and bankroll greenfield hospitals as Q4 profit slumped 69%.

What’s new

Board approved 77,02,182 warrants to promoters at ₹779 each, raising ₹600 cr.
Proceeds earmarked for debt reduction and greenfield hospital projects.
Issue size equals ~15% of annual revenue, crossing materiality threshold.

Why it matters

Promoters are putting ₹600 cr of their own money into a company where net profit just dropped 69% year-on-year. That is a strong conviction signal, but the 11% dilution over 18 months creates near-term uncertainty, especially with a ₹1,500 cr QIP still on the table.

What we’re watching

Shareholder approval at the EGM on July 9, 2026.
Whether the QIP plan (₹1,500 cr) is shelved or pursued concurrently.
Impact on debt/equity (currently 0.89) after debt repayment.

The full read

The board approved a preferential issue of 77,02,182 warrants to promoter entities (Dr. Abhinay Bollineni, Mr. Adwik Bollineni, and Bharas Ventures LLP) at ₹779 per warrant, raising ₹600 crore. This amount equals 15% of annual revenue of ₹3,905 crore, crossing the materiality threshold for a mid-cap company. Proceeds will retire debt (debt/equity stands at 0.89) and fund greenfield hospitals. The news follows a tough Q4 FY26 where net profit plunged 69% to ₹31 crore on expansion costs, and the company had previously flagged a ₹1,500 crore QIP plan. Promoters putting their own money at this stage is a strong vote of confidence, but the 11% dilution over 18 months and the unresolved QIP overhang weigh on sentiment. The ₹600 crore infusion gives KIMS firepower to reduce debt and grow, but execution will determine whether this move lifts or burdens the stock.

Primary source: BSE · NSE

KIMS plans ₹1,500 cr QIP as profit slides 69% on expansion drag

Tipsheet Editorial — Fri, 22 May 2026 14:40:31 GMT

Revenue grew 35% to ₹1,084 cr, but new units in Bangalore, Thane, and Nasik burned ₹32 cr in EBITDA this quarter.

What’s new

Board approved a ₹1,500 cr QIP to trim a debt pile exceeding ₹3,000 cr.
New hospitals contributed ₹224 cr in revenue but posted an aggregate EBITDA loss of ₹32 cr.
Management targets break-even for new units within 12-18 months, pending insurance approvals.

Why it matters

The company is in an aggressive growth phase where revenue gains are currently eclipsed by the high cost of new hospital ramp-ups. The QIP is a necessary move to reset a balance sheet carrying over ₹3,000 crore in debt as the firm builds out its footprint across five states.

What we’re watching

Timeline and pricing of the ₹1,500 cr QIP.
Progress on insurance empanelment for the Bangalore, Thane, and Nasik units.
Whether EBITDA margins can recover from their current 19.9% level.

The full read

Krishna Institute of Medical Sciences (KIMS) finished Q4 FY26 with a stark disconnect between top-line growth and bottom-line health. While revenue climbed 35% to ₹1,084 crore, profit plunged 69% to ₹33 crore as the company absorbed an EBITDA loss of ₹32 crore from its recently opened hospitals in Bangalore, Thane, and Nasik. These new units represent a significant drag on margins, which slipped to 19.9% this quarter. To clear the runway for expansion into Karnataka, Kerala, Tamil Nadu, Andhra Pradesh, and Telangana, KIMS is tapping the market for a ₹1,500 crore QIP. The priority is to deleverage a balance sheet burdened by over ₹3,000 crore in debt. Management expects the new hospitals to turn profitable within 12-18 months, though success hinges entirely on securing insurance empanelment. Until those approvals land, the high overheads of the expansion strategy will continue to weigh on the company's profitability.

Primary source: BSE · NSE